dementia

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

BridgeBio’s big week, Lilly’s Alzheimer’s data, & succession at Stanford

Biotech Rachel Cohrs

STAT Plus: Medicare to cover more brain scans for Alzheimer’s patients

Biotech Adam Feuerstein

STAT Plus: Detailed data confirm benefits — and risks — of Eli Lilly’s Alzheimer’s drug

In the Lab Andrew Joseph

Researchers turn to CRISPR to unlock one of the trickiest diseases to treat: Alzheimer’s

Biotech Andrew Joseph

STAT Plus: With momentum on Alzheimer’s therapies, Europe sees delivery challenges ahead, too

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Wegovy in the brain, pivotal Alzheimer’s data, & pulling Threads

Health Rachel Cohrs

STAT Plus: How are insurers handling the Alzheimer’s drug Leqembi and related scans?

Biotech Brittany Trang

STAT Plus: Eisai executive who helped lead development of Alzheimer’s drug to retire

First Opinion Howard M. Fillit

We finally have new Alzheimer’s drugs. How do we decide who gets them?

Biotech Adam Feuerstein and Damian Garde

STAT Plus: FDA approves first Alzheimer’s therapy shown to clearly slow cognitive decline

Biotech Matthew Herper

STAT Plus: With savvy bets, a dynamic duo makes Eli Lilly one of pharma’s biggest success stories

First Opinion Podcast Torie Bosch

Listen: Is the medical system ready for Alzheimer’s drugs that work?

First Opinion Jason Karlawish

The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Exec nominated to Biogen board is mother of outgoing director’s child; telehealth company pauses Wegovy ads amid shortages

Biotech Adam Feuerstein and Damian Garde

STAT Plus: FDA panel unanimously endorses Eisai’s Alzheimer’s drug

Biotech Adam Feuerstein and Damian Garde

STAT Plus: Tracking the FDA advisory panel on Eisai and Biogen’s treatment for Alzheimer’s disease

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Politics Rachel Cohrs

STAT Plus: Democrats blast Biden administration over Alzheimer’s drug plans

Politics Rachel Cohrs

STAT Plus: Medicare holds firm on Alzheimer’s drug coverage policy

Politics Kerry Dooley Young

STAT Plus: Will Medicare cover it? Drugs like Aduhelm are challenging its standard

D.C. Diagnosis Sarah Owermohle

FDA budget battles, prisons’ sobering Covid response & BIO’s CEO search is on

In the Lab Andrew Joseph

Study: Rare genetic mutation appears to have protected second person from early Alzheimer’s

Health Kay Lazar — Boston Globe

STAT Plus: Cracking an intriguing secret of centenarians: Why so few are ravaged by Alzheimer’s disease

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Lilly’s Alzheimer’s success, a milestone FDA approval, & Moderna’s shrinking business

Politics Rachel Cohrs

STAT Plus: New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

In the Lab Jonathan Wosen

Don’t ignore potential microbial causes of Alzheimer’s and other chronic diseases, researchers say

Biotech Damian Garde

STAT Plus: For Eli Lilly’s head scientist, Alzheimer’s results cap a 25-year scientific quest

Biotech Matthew Herper and Adam Feuerstein

STAT Plus: Eli Lilly’s Alzheimer’s therapy slowed patients’ rate of cognitive decline, data show

Biotech Adam Feuerstein and Damian Garde

STAT Plus: What to know about the upcoming readout of Eli Lilly’s experimental Alzheimer’s therapy